September 30, 2022
2 min watch
Save
VIDEO: SpyGlass CEO gives update on IOP-lowering drug delivery platform
Issue: November 10, 2022
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video from Eyecelerator@AAO, SpyGlass Pharma CEO Patrick Mooney discusses the company’s drug delivery platform, which lowered IOP in patients with open-angle glaucoma or ocular hypertension.
“We’re all about long-term drug delivery, and our long-term drug delivery platform gives the physicians the ability to treat patients and gives patients a little holiday from their drops,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Mooney P. SpyGlass Pharma. Presented at: Eyecelerator@AAO; Sept. 29, 2022; Chicago.
Disclosures:
Mooney reports being the CEO of SpyGlass Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.